Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Westblade LF, Simon MS, Satlin MJ. Bacterial Coinfections in Coronavirus Disease 2019. Trends Microbiol. 2021;29(10):930-941.

Hu Q, Poulose N, Girmay S, Helevä A, Doultsinos D, Gondane A, et al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biol. 2021:1-8.

Wang TZ, Simon MS, Westblade LF, Saiman L, E Furuya Y, Calfee DP. Quantitative characterization of high-touch surfaces in emergency departments and hemodialysis facilities. Infect Control Hosp Epidemiol. 2021;42(4):474-476.

Shohdy KS, Bareja R, Sigouros M, Wilkes DC, Dorsaint P, Manohar J, et al. Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. NPJ Genom Med. 2021;6(1):66.

Punjani N, Flannigan R, Kang C, Khani F. Quantifying Heterogeneity of Testicular Histopathology in Men with Nonobstructive Azoospermia. J Urol. 2021;206(5):1268-1275.

Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med. 2021;145(4):461-493.

Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplant Cell Ther. 2021;27(8):697.e1-697.e5.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Sakunrangsit N, Metheepakornchai P, Kumpunya S, Greenblatt MB, Leelahavanichkul A, Pisitkun P, et al. Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model. PLoS One. 2021;16(4):e0250215.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.